Перспективы микробной терапии в современной медицине
https://doi.org/10.31146/1682-8658-ecg-239-7-5-11
Аннотация
На современном уровне научных знаний об организации биологических систем роль микроорганизмов в их функционировании представляется вполне очевидной. Однако, значение микроорганизмов и роли нарушения микроэкологии в развитии патологий соматического характера до сих пор не является предметом споров и дискуссий. Данная обзорная статья посвящена разъяснению позиции автора, касающейся современных перспектив использования микроорганизмов в качестве средств коррекции дисбиотических состояний. Обсуждается как использование чужеродных микроорганизмов в виде пробиотиков или фекальных трансплантатов, так и перспектива применения собственных, индигенных бактерий для восстановления индивидуальных микробиоценозов человека и животных.
Об авторе
А. Н. Суворов
Федеральное государственное бюджетное научное учреждение «Институт Экспериментальной Медицины»
Россия
Россия
Список литературы
1. Peixoto R.S., Sweet M., Villela H.D.M., Cardoso P., Thomas T., Voolstra C.R., Høj L., Bourne D.G. Coral Probiotics: Premise, Promise, Prospects. Annu Rev Anim Biosci. 2021 Feb 16;9:265-288. doi: 10.1146/annurev-animal-090120-115444.
2. Cabreiro F., Gems D. Worms need microbes too: microbiota, health and aging in Caenorhabditis elegans. EMBO Mol Med. 2013 Sep;5(9):1300-10. doi: 10.1002/emmm.201100972.
3. Engel P., Moran N.A. The gut microbiota of insects - diversity in structure and function. FEMS Microbiol Rev. 2013 Sep;37(5):699-735. doi: 10.1111/1574-6976.12025.
4. Heintz-Buschart A., Wilmes P. Human Gut Microbiome: Function Matters. Trends Microbiol. 2018 Jul;26(7):563-574. doi: 10.1016/j.tim.2017.11.002.
5. Warinner C., Speller C., Collins M.J., Lewis C.M. Jr. Ancient human microbiomes. J Hum Evol. 2015 Feb;79:125-36. doi: 10.1016/j.jhevol.2014.10.016.
6. Nelson B.N., Friedman J.E. Developmental Programming of the Fetal Immune System by Maternal Western-Style Diet: Mechanisms and Implications for Disease Pathways in the Offspring.Int J Mol Sci. 2024 May 29;25(11):5951. doi: 10.3390/ijms25115951.
7. Lederberg J. Infectious history. Science. 2000;288(5464):287-293. doi: 10.1126/science.288.5464.287.
8. Pendse M., Hooper L.V. Immunology: Mum’s microbes boost baby’s immunity. Nature. 2016 May 5;533(7601):42-3. doi: 10.1038/nature17895.
9. Tiffany C.R., Bäumler A.J. Dysbiosis: from fiction to function. Am J Physiol Gastrointest Liver Physiol. 2019 Nov 1;317(5): G602-G608. doi: 10.1152/ajpgi.00230.2019.
10. Liang D., Wu F., Zhou D., Tan B., Chen T.Commercial probiotic products in public health: current status and potential limitations. Crit Rev Food Sci Nutr. 2024;64(19):6455-6476. doi: 10.1080/10408398.2023.2169858.
11. Luzzi A., Briata I.M., Di Napoli I., Giugliano S., Di Sabatino A., Rescigno M., Cena H. Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome. Clin Nutr. 2024 Jun;43(6):1433-1446. doi: 10.1016/j.clnu.2024.04.032.
12. Hatfull G.F., Dedrick R.M., Schooley R.T. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annu Rev Med. 2022 Jan 27;73:197-211. doi: 10.1146/annurev-med-080219-122208.
13. Bals R., Weiner D.J., Moscioni A.D., Meegalla R.L., Wilson J.M. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immunol. 1999;67:6084-9. doi: 10.1128/IAI.67.11.6084-6089.1999.
14. Wilson C.L., Ouellette A.J., Satchell D.P. et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999 Oct 1;286(5437):113-7. doi: 10.1126/science.286.5437.113.
15. Birchler T., Seibl R., Büchner K., Loeliger S., Seger R., Hossle J.P., Aguzzi A., Lauener R.P. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol. 2001 Nov;31(11):3131-7. doi: 10.1002/1521-4141.
16. Ayabe T., Satchell D.P., Wilson C.L., Parks W.C., Selsted M.E., Ouellette A.J. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol. 2000 Aug;1(2):113-8. doi: 10.1038/77783.
17. Shendereov B.A., Manvelova M.A., Stepanchuk Iu.B., Skiba N.E. Probiotiki i funktsional’noe pitanei [Probiotics and functional food]. Antibiot Khimioter. 1997;42(7):30-4.Russian. PMID: 9334147.
18. Suvorov A., Simanenkov V., Gromova L. et al. Enterococci as probiotics or autoprobiotics, in “Prebiotics and probiotics potential for human health” 18 April, 2011, Sofia, pp. 104-112.
19. Ermolenko E., Gromova L., Borschev Y. et al. Influence of different probiotic lactic Acid bacteria on microbiota and metabolism of rats with dysbiosis. Biosci Microbiota Food Health. 2013;32(2):41-9. doi: 10.12938/bmfh.32.41.
20. Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an Approach for Restoration of Personalised Microbiota. Front Microbiol. 2018 Sep 12;9:1869. doi: 10.3389/fmicb.2018.01869.
21. Ermolenko E., Koroleva I., Suvorov A. «Microbial Therapy with Indigenous Bacteria: From Idea to Clinical Evidence.» Microbiome in 3P Medicine Strategies: The First Exploitation Guide. Cham: Springer International Publishing, 2023. 251-274. doi: 10.1007/978-3-031-19564-8_9.
22. Ermolenko E., Sitkin S., Vakhitov T. et al. Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome. Benef Microbes. 2023 Apr 18;14(2):119-130. doi: 10.3920/BM2022.0053.
23. Baryshnikova N.V., Ilina A.S., Ermolenko E.I., Uspenskiy Y.P., Suvorov A.N. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases. 2023 Jul 16;11(20):4740-4751. doi: 10.12998/wjcc.v11.i20.4740.
24. Koroleva I.V., Mikhaylova E.S., Zhukovskaia E.S., Kraeva L.A., Suvorov A.N. Clinical and microbiological evaluation of the efficacy of autoprobiotics in the combination treatment of chronic generalized periodontitis. Revista Latinoamericana de Hipertensión. 2021;16(1), 15-32.
25. Ermolenko E., Baryshnikova N., Alekhina G. et al. Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period. Microorganisms. 2024;12:980. doi: 10.3390/ microorganisms12050980.
26. Artemev I.A., Ermolenko E.I., Kotyleva M.P. et al. Use of autoprobiotics in the complex therapy of axial spondyloarthritis.Russian Journal for Personalized Medicine. 2023;3(1):80-97. (In Russ.) doi: 10.18705/2782-38062023-3-1-80-97.
27. Baktash A., Terveer E.M., Zwittink R.D., Hornung B.V.H., Corver J., Kuijper E.J., Smits W.K. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Front Microbiol. 2018 Jun 12;9:1242. doi: 10.3389/fmicb.2018.01242.
28. Stripling J., Rodriguez M. Current Evidence in Delivery and Therapeutic Uses of Fecal Microbiota Transplantation in Human Diseases - Clostridium difficile Disease and Beyond. Am J Med Sci. 2018 Nov;356(5):424-432. doi: 10.1016/j.amjms.2018.08.010.
29. Baron T.H., Kozarek R.A. Fecal microbiota transplant: we know its history, but can we predict its future? Mayo Clin Proc. 2013 Aug;88(8):782-5. doi: 10.1016/j.mayocp.2013.06.007.
30. Olesen S.W., Panchal P., Chen J., Budree S., Osman M. Global disparities in faecal microbiota transplantation research. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):241. doi: 10.1016/S2468-1253(19)30452-2.
31. Osman M., Budree S., Kelly C.R., Panchal P., Allegretti J.R., Kassam Z; OpenBiome Collaborators. Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study. Gastroenterology. 2022 Jul;163(1):319-322. doi: 10.1053/j.gastro.2022.03.051.
32. D Goldenberg S., Merrick B. The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection. Ther Adv Infect Dis. 2021 Jan 25;8:2049936120981526. doi: 10.1177/2049936120981526.
33. Olesen S.W., Panchal P., Chen J., Budree S., Osman M. Global disparities in faecal microbiota transplantation research. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):241. doi: 10.1016/S2468-1253(19)30452-2.
34. Green J.E., Davis J.A., Berk M. et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes. 2020 Nov 9;12(1):1-25. doi: 10.1080/19490976.2020.1854640.
35. Rinott E., Youngster I., Yaskolka Meir A. et al. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology. 2021 Jan;160(1):158-173.e10. doi: 10.1053/j.gastro.2020.08.041.
36. Malard F., Vekhoff A., Lapusan S. et al. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun. 2021 May 25;12(1):3084. doi: 10.1038/s41467-021-23376-6.
37. Bulow C., Langdon A., Hink T. et al. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential. mSphere. 2018 Nov 21;3(6): e00588-18. doi: 10.1128/mSphereDirect.00588-18.
38. Basson A.R., Zhou Y., Seo B., Rodriguez-Palacios A., Cominelli F. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res. 2020 Dec;226:1-11. doi: 10.1016/j.trsl.2020.05.008.
39. Ermolenko E., Kotyleva M., Kotrova A. et al. Consortium of Indigenous Fecal Bacteria in the Treatment of Metabolic Syndrome. Microorganisms. 2022; 10(8):1574. doi: 10.3390/microorganisms10081574.
Рецензия
Для цитирования:
Суворов А.Н. Перспективы микробной терапии в современной медицине. Экспериментальная и клиническая гастроэнтерология. 2025;(7):5-11. https://doi.org/10.31146/1682-8658-ecg-239-7-5-11
For citation:
Suvorov A.N. Prospects for microbial therapy in modern medicine. Experimental and Clinical Gastroenterology. 2025;(7):5-11. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-239-7-5-11
Просмотров:
19
JATS XML
Послать статью по эл. почте 
